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Abstract
Alanine Serine Cysteine Transporter 2 (ASCT2) is a member of the solute carrier 1A
(SLC1A) family of transport proteins. It is a Na+ dependent, obligatory neutral amino acid
exchanger with the capability to transport glutamine and it is a primary glutamine transport
protein in cancer cells. This glutamine transport capability confers an important physiological
role for ASCT2 in the maintenance of intracellular amino acid pools for various metabolic and
cell signaling pathways. Because of this, ASCT2 is found to be overexpressed in many cancers,
which rely heavily on glutamine as an essential nutrient for cell survival and growth. A wealth of
research demonstrating overexpression of ASCT2 in cancer cells has made it a target for the
synthesis of specific pharmacological inhibitors with the goal of killing cancer cells by glutamine
starvation. A recent class of compounds known as AABA (2-amino-4-bis (aryloxy benzyl)
amino butanoic acids) have been reported to have high binding affinity to ASCT2 and inhibit its
function. The specificity of these inhibitors was contested and it was found that two of the most
potent compounds synthesized, Compound 12 and V-9302, do not bind to ASCT2, but instead
inhibit the function of two membrane transporters of different families, SNAT2 and LAT1.
However, electrophysiological characterization of these inhibitors to either ASCT2 or SNAT2
has not been reported in the literature. Electrophysiological characterization has several benefits,
including its high time resolution and accurate current recordings of membrane transport
processes, that make it useful for measuring kinetic parameters associated with substrate or
inhibitor binding such as Ki values. Herein we present the first electrophysiological
characterization of several AABA compounds towards ASCT2 and SNAT2 by whole cell patch
clamp current recordings and illustrate that each tested compound show variability in their
inhibition toward ASCT2 or SNAT2, with some compounds presenting as more potent inhibitors
iv

of ASCT2 while others as more potent inhibitors of SNAT2. However, each compound was
shown to bind to and inhibit the protein in some manner, some, albeit, at much higher
concentrations than reported in the literature. Notably some of the tested compounds are the first
known blockers of SNAT2 transport.
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Chapter 1: Introduction
1.1: Metabolism in Cancer Cells: A Brief Overview
Unlike normally functioning cells, cancer cells undergo a shift in metabolism. This shift
includes several changes that make cancer cells distinct from normal, healthy cells. There is a
preferred metabolic shift towards glycolysis, even in aerobic environments, known as the
Warburg effect (Liberti, M. V, & Locasale, J. W., 2016). Additionally, there is an increase in
glutamine uptake observed in cancer cells. Glutamine is the most abundant amino acid found in
plasma, making it a plentiful resource for cancer cells to utilize (Souba, W. W., 1993). An
important use of glutamine by cancer cells is as a catabolic substrate that can be broken down
into citric acid cycle metabolites in a process known as glutaminolysis (Yang, L. et al., 2017).
Glutamine is a fundamental amino acid for the proliferation, growth, and survival of cancer cells,
therefore, targeting proteins that regulate glutamine uptake into cancerous cells is a field of
research with high potential for future clinical applications in cancer treatments (Souba, W. W.,
1993).
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Figure 1: Schematic diagram of glutaminolysis as it occurs in the mitochondria by transport of
glutamine through ASCT2 (Jin, L. et al., 2016).
As illustrated in Figure 1, glutamine is important in normal cell process such as
glutaminolysis, where glutamine is broken down and fed into the citric acid cycle in the form of
α-ketoglutarate. This process occurs in normal healthy cells, but it is seen in significantly higher
volumes in cancer cells than in normal cells (Yang, L., Venneti, S., & Nagrath, D., 2017). This is
just one of the ways that cancer cells utilize the high concentration of plasma glutamine. The
other ways that glutamine is utilized include activation and sustaining cell growth signaling
pathways such as mTOR (mammalian target of rapamycin), increased glucose uptake by
suppression of proteins that regulate glucose uptake, and increased resistance to cell senescence
and cell death (Hensley, C. T. et al., 2013).
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1.2: ASCT2: Alanine Serine Cysteine Transporter 2: Background
ASCT2 is a membrane bound transport protein that belongs to the solute carrier 1A
family (SLC1A) of membrane transport proteins and is an important protein in the regulation of
the concentrations of extracellular and intracellular amino acid pools. It is unique in that it is the
only member of this family with the ability to transport glutamine, making it an important
component for glutamine metabolism (Napoli, E et al., 2018). Because of this, ASCT2 plays a
significant role in the growth and survival of cancer cells, which rely more heavily on glutamine
than normal cells, and it is highly upregulated with much higher expression than normal cells.
These include cancers such as breast cancer and prostate cancer, making it a target of interest for
the synthesis of pharmacological inhibitors (Wang, Q et al., 2015; Van Geldermalsen, M et al.,
2016). Because of their potential as effective targets for the treatment of various cancers, the
synthesis and testing of ASCT2 inhibitors has become a rapidly growing field of research.
1.3: ASCT2: Crystal Structures, Binding Site Characterization, and Transport Mechanism
ASCT2 or SLC1A5 is an electroneutral amino acid exchanger, in which amino acid
transport is coupled to the co-transport of Na+ ions but is not driven by this transport through a
secondary active transport mechanism (Bröer A. et al., 2000). The electroneutrality of ASCT2
means that it does not produce a change in the membrane potential of the cell. Unlike the
excitatory amino acid transporters (EAAT’s) and the archaeal prokaryotic transporters, GltPh and
GltTk, other members of the SLC1A family of glutamate transporters, which are electrogenic and
undergo concentrative acid amino acid transport (Divito, C. B., & Underhill, S. M., 2014; Ji, Y et
al., 2016; Scopelliti, A. J. et al., 2018). However, structural characterization of the members of
this family has allowed for the development of homology models used to further understand the
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structural basis of neutral amino acid exchange in the SLC1A family and to elucidate important
substrate binding residues in ASCT2 by sequence alignments and reverse mutagenesis to more
fully understand ASCT2’s specificity to glutamine (Scopelliti, A. J. et al., 2018). Furthermore,
ASCT2 follows an antiporter mechanism in which Na+ ions and a neutral amino acid from the
extracellular portion of the cell membrane are exchanged for a neutral amino acid on the
intracellular side (Utsunomiya-Tate et al., 1996; Kanai & Hediger, 2004). In addition, ASCT2,
along with the rest of the proteins in the SLC1A family, has a thermodynamically uncoupled leak
anion conductance, in which ASCT2 allows anions like SCN- to flow across the cell membrane
through it (Broer A. et al., 2000; Grewer, C., & Grabsch, E., 2004). This leak anion conductance
is the basis for electrophysiological characterization of ASCT2 because in the presence of
substrates such as alanine, at 0 mV, inwardly directed currents are observed, while in the
presence of inhibitors, apparent outwardly directed currents are observed as an indication of the
inhibition of the leak anion conductance (Grewer, C., & Grabsch, E., 2004). The direction of the
currents depends on the experimental buffer conditions used, but the trend is still consistent.
Additionally, recent crystal structures have revealed that it is a homotrimeric protein and its three
identical monomers each contain a scaffold and transport domain (Yu, X. et al., 2019). In recent
years, an inward open crystal structure of ASCT2 has elucidated a possible mechanism for
ASCT2 substrate transport by a one gate elevator mechanism in which the specific hairpin loop,
HP2, acts as the gate on both the extracellular and intracellular substrate binding domains of the
protein. The substrate is translocated through the cellular membrane through conformational
changes of the transport domains of the protein, while the scaffold domains remain stationary
(Garaeva, A. A. et al., 2019; Yu, X. et al., 2019). A recent outward open cryo-EM structure of
ASCT2, in combination with the inward facing state, has elucidated more information about
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specific loops and structures within the protein that are critical to the transport mechanism of
ASCT2 (Yu, X. et al., 2019). The recently proposed one gate elevator mechanism is illustrated
in Figure 2, in addition to the electroneutral exchange mechanism of ASCT2 in Figure 3.

Figure 2: Proposed one gate elevator mechanism for substrate translocation in ASCT2. In the Na+
dependent process, the substrate binds to the substrate binding site in the transport domain in the
outward open conformation. After closing of HP2, conformational changes allow for exchange of
substrate to the intracellular side of the cell. Release of the extracellular substrate in the intracellular
site allows for binding of an intracellular amino acid (Garaeva, A. A. et al., 2019).

Figure 3: Ion exchange mechanism of ASCT2 that occurs during amino acid exchange. In
addition, the direction of the thermodynamically uncoupled anion conductance is illustrated as
well. This figure was provided by Elias Ndaru.
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Amino acid exchange in normal physiological conditions for ASCT2 is electroneutral, as
illustrated by the stoichiometry of Na+ exchange. The uncoupled anion conductance is what
causes changes in potential across the membrane and produces currents for analysis and
calculation of kinetic constants. Interestingly, chloride anions are not permeable to the anion
conducting pore and the physiological significance of this pore is not known, as SCN- anions are
not present in the extracellular or intracellular medium of cells. However, the significance of this
anion conductance comes from the ability of researchers to use electrophysiology to characterize
kinetic constants for inhibitors and substrates using currents produced by anion conductance in a
dose dependent manner (Broer A. et al., 2000; Grewer, C., & Grabsch, E., 2004).
1.4: SNAT2: Sodium Coupled Neutral Amino Acid Transporter 2
SNAT2 is an electrogenic neutral amino acid transporter, that is coupled to intracellular
transport of one Na+ ion through a symporter mechanism (Zhang, Z. et al., 2011). SNAT2
belongs to the solute carrier 38 transporter family, SLC38, which is involved with the
unidirectional transport of neutral amino acids into the cell, including glutamine. SNAT2 falls
mainly under the category of system A activity, which is associated with transport of short chain
aliphatic amino acids specifically into the cell, and therefore regulation of intracellular amino
acid pools (Bröer, S., 2014).

6

Figure 4: Electrogenic co-transport of one Na+ ion for each amino acid transported via SNAT2.
This figure was provided by Elias Ndaru.

As illustrated in Figure 4, amino acid transport by SNAT2 is an electrogenic process
(Zhang, Z. et al., 2011). Additionally, it plays an important role in the osmotic regulation of cell
volume in hypertonic conditions (Franchi-Gazzola, R. et al., 2004). Furthermore, and an
important reason for it as a target of interest, is the upregulation of SNAT2 in conditions of
amino acid starvation (Hoffmann, T. M. et al., 2018). Upregulation of SNAT2 in ASCT2
knockdown conditions, and therefore amino acid starvation conditions, has been shown to be a
rescue response in cancer cells, indicating that it plays an important role in maintaining
glutamine uptake in cancer cells and therefore a target for the synthesis of pharmacological
inhibitors (Bröer, A., et al., 2016).
1.5: AABA inhibitors: ASCT2 Specific or Off-Target Effects?
Previous inhibitors of ASCT2 have been reported in the literature, such as L -γ- glutamylp-nitroanilide (GPNA). However, GPNA has a poor binding affinity to ASCT2 and has been
demonstrated to be nonspecific in its inhibition (Esslinger, C. S. et al., 2005; Corti, A. et al.,
2019). Additionally, other compounds based on sulfonamide and sulfonic acid ester scaffolds
have been characterized by electrophysiological methods and have been reported as inhibitors for
7

ASCT2 with Ki values as low as 8 ± 4 µM (Ndaru, E., et al., 2019). Other studies have also
reported benzyl proline derivatives as effective ASCT2 inhibitors using electrophysiological
characterization, with the lowest reported Ki value of 3 ± 2 µM for a biphenyl benzyl proline
compound (Singh, K. et al., 2017). Recent compounds in the class of 2-amino-4-bis (aryloxy
benzyl) amino butanoic acids (AABA) have been purported to be specific inhibitors of ASCT2
with IC50 values in the range of 1-10 µM for the most potent inhibitors of human ASCT2
(hASCT2) and rat ASCT2 (rASCT2) (Schulte, M. L. et al., 2016). IC50 and Ki are two ways to
characterize inhibitor binding affinity in enzyme-substrate complexes, but it can be applied to
inhibitor binding of transport proteins as well. IC50 values differ from Ki values because Ki
values are a constant value for a specific inhibitory compound while IC50 values can vary
depending on the experimental assay used and are the concentration of inhibitor needed to reduce
enzymatic activity by one half the maximum in the specific conditions. In enzyme-inhibitor
assays, the IC50 value will change with changing substrate concentrations at constant inhibitor
concentrations while the Ki value for the inhibitor will remain constant. Ki values will always be
lower than IC50 values, as they essentially represent the intrinsic inhibitor binding affinity
(Burlingham, B. T., & Widlanski, T. S., 2003). This study characterized the IC50 values for a
library of AABA compounds using a 3H labelled glutamine uptake assay with increasing
inhibitor concentrations and concluded that the inhibition constants obtained were from
inhibition specific to ASCT2 in both HEK293 (human embryonic kidney cell line 293) and C6
(rat glial tumor cells) (Schulte, M. L. et al., 2016). In addition, researchers from this group
synthesized a novel compound from the AABA scaffold known as V-9302, and they
demonstrated in a variety of cancer cell lines that this compound inhibits viability, growth, and
survival of tumor cells in vitro and in vivo in mice by the inhibition of glutamine uptake in
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ASCT2 (Schulte, M. L. et al., 2018). However, recent experimental assays have shown that the
AABA inhibitors, Compound 12 and V-9302 may not be specific to ASCT2, but instead, the
possibility was proposed that they are inhibitors of the membrane proteins SNAT2 (sodium
dependent neutral amino acid transporter) and LAT1 (large neutral amino acid transporter),
which are also upregulated and critical to cancer metabolism (Bröer, A. et al., 2018). These
experiments showed that inhibition of glutamine uptake in the presence of AABA inhibitors with
cells containing ASCT2 and cells with ASCT2 deletions showed identical inhibition.
Additionally, through glutamine uptake experiments, these researchers discovered a large
inhibition of system A activity in cells without ASCT2, that expressed SNAT2, indicative that
these compounds inhibit SNAT2 and not ASCT2. Additionally, it was discovered that AABA
compounds inhibit LAT1 activity as well (Bröer, A. et al., 2018). LAT1 is another relevant
protein that is an antiporter of essential amino acids and plays an important role in cancer
metabolism and import of leucine for use in cell signaling pathways (Scalise, M., et al., 2018). In
addition, there have been no tests using electrophysiological methods to characterize the binding
affinity of AABA compounds to ASCT2 and SNAT2. Here, we use electrophysiological
characterization to determine the Ki values for four AABA compounds reported in Schulte et al.
(2016 & 2018), in addition to a derivative with a single side chain. Two of these compounds,
compound 12 and V-9302, were tested by Bröer, A. et al. (2018) and were determined to have
off target, nonspecific effects, in the inhibition of glutamine uptake by ASCT2. The other two
inhibitors, compound 6 and compound 19, have not been tested by our group or others. The
literature reported IC50 values and the structure of these compounds is illustrated in Figure 5.
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Figure 5: AABA based compounds tested by electrophysiology and their purported literature
IC50 values (Schulte, M. L. et al., 2016 & 2018). Compound 19 single is referred to as 19s
throughout the paper.
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1.6: The Patch Clamp: Set-up, Important Principles, and its Application to the Characterization
of ASCT2 and SNAT2 Inhibitors
Here we use electrophysiological techniques in the form of whole cell voltage clamp
current recording (patch clamp) to measure transient steady state currents produced by substrate
or inhibitor binding to ASCT2 and SNAT2. The patch clamp technique is useful in this context
because it can be used to determine kinetic constants associated with substrate or inhibitor
binding, such as Ki values. In addition, the patch clamp technique confers several advantages in
this experimental characterization because of its sensitivity, high time resolution, and it does not
require fluorescent or radioactively labelled substrates (Grewer, C. et al., 2013). A diagram of
the current recording system used in the whole cell patch clamp set up is illustrated in Figure 6.

Figure 6: Currents produced by cellular process, such as ion conductance, are measured by the
flow of different ions between the cell, which is buffered by an internal salt solution that is
present inside the pipette, and the extracellular solution. Currents are recorded by silver
microelectrodes present in both the micropipette and external solution. (Molecular Devices,
2012).
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The patch clamp technique is a technique in which a micropipette filled with an internal
salt solution is pressed onto a cell, and a small amount of suction is applied to break the plasma
membrane. As illustrated in Figure 6, the pipette contains an Ag/AgCl microelectrode used to
record these currents, in addition to one inside the extracellular buffer. By breaking the plasma
membrane, the cell can enter “whole cell” recording mode, in which the pipette is in
communication with the entirety of the cell cytosol, and therefore all the ASCT2 proteins being
expressed within the cell membrane. A small voltage pulse can also be applied to the membrane
to break it into whole cell mode (Molecular Devices, 2012). By being in communication with the
entirety of the cell, the sum of all the currents produced by leak anion conductance of every
expressed ASCT2 protein can be measured simultaneously. Currents are measured without
changes in voltage because the voltage is clamped to a constant value by injection of an
appropriate current (Grewer, C. et al., 2013). For ASCT2, the internal solution contains 130 mM
NaSCN as the major ions, while the external solution contains 140 mM NaCl. In its normal
resting state, ASCT2 has a natural leak anion conductance, enabling the transmembrane flow of
anions down their concentration gradient (Grewer, C., & Grabsch, E., 2004). In the given
experimental conditions, SCN- flows down its concentration gradient from the intracellular to the
extracellular side of the cell. This can be observed in the patch clamp set up as a more positive
membrane potential when the recording enters whole cell mode. However, with substrate bound,
this leak anion conductance is increased, leading to the production of inwardly directed currents.
In the presence of inhibitors, this leak anion conductance is inhibited, and leads to the production
of apparent “outwardly” directed currents (Grewer, C., & Grabsch, E., 2004). This apparent
“outward” current is really caused by the reduction (inhibition) of the inwardly directed tonic
leak anion current. By measuring these currents at a constant voltage with increasing inhibitor
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concentrations, a Ki value for the specific compound for ASCT2 can be calculated based on the
response from the cells via the production of currents. Alanine substrate is placed on the
intracellular side of the solution for ASCT2 to keep it in its activated, outward-facing state for
current recording. This is because alanine on the intracellular side leaves the extracellular
binding site in a position where it is open to accept substrate (Grewer, C. et al., 2013). If values
of the currents produced in increasing inhibitor concentration are plotted to saturation response
and they fit a curve that resembles Michaelis-Menten like enzyme kinetics, then the Hill plot
equation can be used to calculate the Ki value specific to ASCT2 for the compound. The version
used to characterize inhibitor binding affinity by electrophysiology is slightly modified to use
relative current values instead of the typical V/Vmax for the y-value in Figure 7.

𝑦=

𝐼𝑚𝑎𝑥 [𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟]
[𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟] + 𝐾𝑖

Figure 7: Hill Plot equation using current measurements to determine Ki values for inhibitors. Y
is equal to the current at each inhibitor concentration relative to the current produced at the
highest inhibitor concentration (I/Imax).

To produce meaningful analyzed data, the currents for these traditional
electrophysiological inhibitor experiments are normalized to 1 using the largest outward current
produced. Each current is divided by the largest current value in pA at the maximum inhibitor
concentration used, and then plotted against each respective inhibitor concentration to produce a
dose response curve. Additionally, competitive experiments using constant alanine (ASCT2 and
SNAT2 substrate) concentrations in the presence of increasing inhibitor concentrations can be
used to reveal possible competitive inhibition in ASCT2 and SNAT2 by these compounds. If
there is little to no inhibition of the leak anion conductance with solutions of increasing inhibitor
concentration, these competitive experiments can be performed for greater insight into inhibition
13

of ASCT2. However, SNAT2 inhibitors can only be characterized by these competitive
experiments as they only produce inwardly directed currents based on their transport mechanism.
Unlike ASCT2, the internal solution for SNAT2 used is 130 mM KMes. There is a small leak
anion conductance associated with substrate binding of SNAT2, however, it is very small
compared to the one produced by ASCT2 and not useful for measuring currents produced by
inhibitor binding (Zhang, Z., & Grewer, C., 2007). In the presence of SNAT2 inhibitors, the
alanine-induced inwardly-directed transport current is reduced compared to the control with
alanine alone, because inhibition decreases the amount of Na+ ions flowing from the
extracellular solution to the intracellular side, therefore decreasing the magnitude of the inwardly
directed current. For these experiments, a modified version of the Hill plot equation is used. This
is to account for the increase in current values in the direction of negative values towards zero, in
contrast to the previously mentioned experiments, which are only concerned with increasingly
positive currents. The equation used is pictured in Figure 8.

𝑦 = 𝐼1 +

𝐼2 [𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟]
𝐾𝑖 + [𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟]

Figure 8: Equation used to calculate Ki values for inhibitors using data from alanine competition
experiments, where I1 is the current produced by alanine without inhibitor present and I2 is the
current produced by the highest inhibitor concentration in the presence of alanine. Y is equal to
current produced by Inhibitor + Ala divided by the current produced by alanine without inhibitor
(Ndaru, E. et al., 2019).

Each current is divided by the most negative inward current produced, which in each case
should be the alanine control. This is to normalize the values to -1. The currents in these
experiments were recorded at 0 mV, as we are not concerned with the voltage dependence of
inhibitor and substrate binding.
14

Chapter 2: Methods and Materials
2.1: General Procedure for Synthesis and Associated Mechanisms of AABA Compounds
All AABA compounds were synthesized and deprotected by the same procedure, except V-9302,
which was purchased from MedChem Express. Compound 19 was synthesized, purified,
analyzed, and deprotected by Christopher Coble.
2.1.1: Coupling
2-amino-4-bis (aryloxy benzyl) amino butanoic acids (AABA) compounds were
synthesized via a reductive amination synthetic scheme (Schulte, M. L. et al., 2016). The starting
materials included each AABA compounds respective side chain in its benzaldehyde form with
the remaining portion of the side chain ortho to the aldehyde position. 2,4 diamino butanoic acid
was kept constant as the amine used for each synthesis and was the limiting reagent in each
reaction. Compounds coupled to two identical side chains used 3 equivalents of aldehyde, while
compounds coupled to a single side chain used 1.1 equivalents of aldehyde. These two
components were added to a clean, oven-dried, round bottomed flask (RBF) with a magnetic stir
bar. A rubber stopper was placed on the RBF and connected to N2 flow via two needles, for
inflow and outflow, to displace any air in the reaction vessel along with possible moisture, for 510 minutes. Dry dichloromethane (DCM) was added via a 10 mL syringe with an oven dried
needle under N2 to the reaction mixture at 0 °C. The mixture was then stirred for 10 minutes at 0
°C under N2. The rubber stopper was then removed from the RBF and 2 equivalents of sodium
triacetoxy borohydride (NaBH(OAc)3) was added to the reaction mixture. The stopper was
placed back on the vessel and the reaction was stirred at 0 °C for 30 more minutes under N2, then
left to stir for 24 hours at room temperature. Appearance of products was confirmed by
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comparison of starting materials to the reaction mixture via silica thin layer chromatography
(TLC) after 24 hours. TLC plates were analyzed under UV light at 254 nm and then stained in a
solution of 0.2 % ninhydrin and 0.5% acetic acid in butanol to identify the presence of amine
groups. An image of the TLC plate after reaction, a sample synthetic scheme, and the mechanism
associated with the reaction are illustrated in Figure 9, 10, and 11.

Figure 9: General synthetic scheme for the synthesis of AABA compounds (Schulte, M. L. et
al., 2016).

Figure 10: Reductive amination mechanism for the synthesis of AABA compounds. The
reaction mechanism proceeds through an unstable imine intermediate. The addition of the
reducing agent is required to shift the equilibrium in favor of the amine product. For single
coupled side chains, the mechanism ends at the formation of the secondary amine. For products
with two side chains, the mechanism repeats because of the presence of the additional amine
hydrogen to form a tertiary amine (Abdel-Magid, A. F., & Mehrman, S. J., 2006).
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Figure 11: TLC analysis of compound 19 with labeled components for reference. There is a low
concentration of the amine (limiting reagent) indicative that the reaction is near completion. The
reaction components were ran on 3:1 hexane: ethyl acetate and analyzed under UV to visualize
aromatic components (left). UV visible components were circled, and the plate was stained under
ninhydrin (right) to indicate the presence of amines.

2.1.2: Aqueous Workup
Aqueous byproducts and waste were purified from the crude reaction mixture via a workup
with distilled water. The crude mixture was rinsed three times with distilled water and the
organic layer was collected in a dry Erlenmeyer flask, dried over Na2SO4, filtered via suction
filtration, and then concentrated and dried in-vacuo.
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2.1.3: Purification via Flash Silica Gel Column Chromatography
The post workup reaction mixture was then purified via flash silica gel column
chromatography. Reaction mixtures were dissolved in approximately 2 mL of a 3:1 hexane: ethyl
acetate solvent mixture. Glass columns were loaded with silica gel, and silica (the stationary
phase) was then dissolved in hexane (the mobile phase). The dissolved reaction mixture was then
pipetted into the column and topped with glass wool. Increasingly polar solvent mixtures of
hexane/ethyl acetate were then added in 50 mL portions to elute the desired product. Product
elution was determined using TLC and UV light. Di-coupled compounds typically eluted at 25%
ethyl acetate: hexane while single coupled compounds eluted at approximately 35% ethyl
acetate: hexane due to their increased polarity. Pure fractions were collected and analyzed using
400 MHz 1H NMR and 101 MHz 13C NMR spectroscopy. Other spectroscopic methods such as
correlation spectroscopy (COSY) and nuclear overhauser effect spectroscopy (NOESY) were
used for further analysis of each compound. Compounds were dissolved in deuterated
chloroform (CDCl3) for NMR analysis.
2.1.4: Deprotection with 4M HCl/dioxane Under Reflux
Compounds were dried for at least 24 hours in-vacuo. Boc and tertbutyl protection groups
were then deprotected with 4M HCl in dioxane under reflux at 55 °C to yield analytically pure
chloride salts in high yield. Purified compounds were dried for at least 24 hours under high
vacuum in a 10 mL RBF. Reflux apparatus was assembled as shown in Figure 14 while N2 gas
was flowing. 4M HCl/dioxane (72 eq.) was added under N2 gas and the mixture was left to stir
under reflux for 24 hours. Excess HCl/dioxane reagent was removed in vacuo and the oily
residue was dissolved in DCM, then the chloride salt was precipitated by the addition of chilled
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hexane. The presence of product was confirmed via TLC and then 1H and 13C NMR analysis.
The synthetic scheme for this deprotection, an image of the reflux apparatus, and TLC plate is
illustrated in Figure 12, 13, and 14.

Figure 12: General synthetic scheme for the deprotection of AABA compounds (Schulte, M. et
al., 2016).

Figure 13: Example TLC analysis of deprotected compound 6 after precipitation. Product was
dissolved in DCM for this analysis and run in 10% methanol in DCM solvent, then stained in
ninhydrin to yield the TLC plate on the right. Each spot is the same deprotected product.
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Figure 14: Reflux apparatus for deprotection in HCl/dioxane for AABA compounds with
labelled components. The reflux condenser and cold-water flow in/out is necessary to recondense any portion of the reaction mixture that evaporates at the temperatures involved. N2 gas
flows at a slow rate to displace any moisture in the reaction atmosphere, in addition to preventing
the buildup of too much vapor pressure.
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2.2: Cell Culture and Transfection
Rat ASCT2 (rASCT2), human ASCT2 (hASCT2), rat SNAT2 (rSNAT2) and yellow
fluorescent protein (YFP) cDNA’s were used to transiently co-transfect human embryonic
kidney 293 (HEK293) cells using POLYPLUS Jet-prime transfection reagent. Transfection is the
process of introducing a desired DNA sequence of interest into a cell with the goal of expressing
the protein coded for by this sequence (Goedhart, J., et al., 2011). The DNA transfection mixture
consisted of 100 μL of transfection buffer, 2 μL of transfection reagent, 0.5 μg of YFP and 0.5
μg of the respective transporter DNA and the solution was vortexed for 10 seconds.
HEK293 cells were cultured in Dulbecco’s modified eagle medium (DMEM),
supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, and essential amino acid
mix. Cell cultures were kept in a humidified CO2 incubator at 10% CO2. To passage confluent
HEK293 cells, old medium was removed by vacuum suction. Cells in culture flasks were then
washed with phosphate buffered saline (PBS Buffer) and then underwent trypsinization using ~ 1
mL of 1% trypsin. Approximately 2 mL of fresh, sterile filtered DMEM was added to the cells.
Cells were broken apart by trituration. Depending on the concentration of cells, 2-4 drops were
added to a sterile plastic culture dish containing DMEM. The culture dish contained three sterile,
autoclaved 12 mm glass cell culture plates coated with 0.01% poly-L-lysine in PBS to help cells
attach to the surface of these dishes. Subsequently, the DNA transfection mixture was added to
the plastic culture dish and the cells were placed in a 37 °C CO2 incubator between 24-28 hours
before patch clamp experiments were conducted on the cells.
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2.3: Whole Cell Patch Clamp Recording
Inhibitor affinity was measured in the whole cell configuration (see paragraph below)
using a patch clamp set up. Currents were recorded with an EPC7 patch clamp amplifier from
ALA Scientific ® using pClamp 6 data acquisition software. Current values were determined
using Clampfit and analyzed in Microsoft Excel. Data was plotted in Origin lab to formulate
dose response curves and current traces for ASCT2 and SNAT2. For cells transfected with
ASCT2 DNA, the external buffer was 140 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, and 10 mM
HEPES at pH 7.40, while the internal micropipette buffer used was 130 mM NaSCN, 2 mM
MgCl2, 10 mM EGTA, 10 mM alanine, and 10 mM HEPES at pH 7.40. For SNAT2 transfected
cells, the external buffer was the same as ASCT2, while the internal buffer contained 130 mM
KMes and 2 mM Mg (Gluconate)2. Micropipettes were fabricated using the model P-97
Flaming/Brown micropipette puller from Sutter Instrument Co. Glass micropipettes were filled
with internal buffer solution and had seal resistances between 3 and 5 MΩ. Internal salt bridges
were filled with external buffer and steady state currents were recorded at 0 mV using the set up
pictured below. Silver electrodes were previously soaked in bleach to generate an AgCl coating
and were used as the microelectrodes. The setup is pictured in Figure 15.
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Figure 15: Patch Clamp Set-up with appropriate parts of the apparatus labelled.
2.3.1: Preparation of Solutions for Testing.
20 mM inhibitor stock solutions were prepared using deprotected chloride salts of the
AABA compounds dissolved in the appropriate volume of dimethyl sulfoxide (DMSO). Inhibitor
solutions were prepared using increasing volumes of DMSO stock solution dissolved in 140 mM
NaCl external buffer. For competitive inhibition experiments, solutions were prepared with a
constant alanine concentration using a 100 mM alanine stock solution. All solutions prepared and
used for testing in this experiment contained ≤ 2% DMSO. Controls only containing buffer and
DMSO were previously performed and did not show substantial effects on current recordings at
concentrations up to 3% DMSO (Ndaru, E. et al., 2019). Due to solubility issues, the most
concentrated inhibitor solution used was 400 μM. The placement of these inhibitor solutions in
the patch clamp set up is pictured in Figure 16.
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Figure 16: Stopped flow solution dispensing system with 8 Eppendorf tubes containing solution.
The first tube contains external buffer for washing the cell and the second tube contains an
alanine control. Tubes 3 – 8 contain increasing inhibitor concentrations.

2.3.2. Whole-Cell Current Recording and Solution Exchange
To choose a cell expressing the desired DNA, fluorescence is observed using a UV lamp.
Typically, increased fluorescence from co-expressed YFP correlates with increased expression of
the desired transport protein and therefore larger currents. The current recording electrode is
controlled by a micromanipulator, which is used to move the electrode tip into the vicinity of the
cell. Once the pipette tip gently touches the cell surface, a seal between pipette tip and membrane
of at least 100 MΩ is achieved, and a small amount of suction is applied to break the cell
membrane under the patch pipette. If at this point, the pipette is not in communication with the

24

entire cell, also known as whole cell mode, a small voltage can be applied to fully break the
membrane under the patch pipette. Once whole-cell configuration is achieved, the cell is gently
lifted and then placed in front of the solution exchange tube, as shown in Figure 17. In addition,
changes in current in response to a probe square wave voltage pulse are demonstrated in Figure
18 along each step of the process of making the seal and achieving whole-cell configuration.

Figure 17: Position of the cell near the solution exchange (left) and high magnification view of a
pipette tip touching a cell (right).

Figure 18: The appearance of current when the pipette is immersed in buffer solution (A), when
the pipette touches the cell (B), when a small portion of the plasma membrane is sucked into the
pipette tip (C), and whole cell mode (D).
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Chapter 3: Results
3.1: Synthesis
Compounds were synthesized in analytically pure yields using reductive amination
according to the synthetic scheme provided by Schulte et al. (2016). Overall, no difficulties were
encountered during the initial coupling, aqueous workup, and purification by column
chromatography. Both di-coupled products and suspected mono-coupled products appeared on
TLC, however, syntheses focusing on the di-coupled products typically had very little of these
side products and were easily purified by column chromatography. Yields of the coupled
products were similar, and in some cases higher compared to the reported literature values (5275%), except for compound 12, which had a yield of 35% deprotected compound (Schulte, M., et
al., 2016). However, difficulties in the synthesis for each compound mainly came with the
deprotection step. Precipitation of the product into a salt came with difficulties during filtration,
as the compound would turn into an oil if left on the suction filter for a short period of time.
Methods were needed to improve the filtration, so each compound was dissolved in a very small
volume of DCM (< 1 mL), precipitated using ~ 3 mL of chilled hexane, and then centrifuged in a
20 mL glass vial at 9000 rpm for ~ 3 minutes. Approximately 3-5 mL of hexane was added, the
solution was placed in a sonicator for 10 minutes, and then was centrifuged again. This
procedure was repeated 2 more times. However, while TLC analysis showed a large abundance
of the deprotected product for most compounds, compound 6 and 12 exhibited a very small spot
with higher Rf value than the product that was fluorescent and stained in ninhydrin. It was
suspected that this was partially deprotected product and it could not be removed regardless of
the number of rinses. Mono-coupled compound 19s poorly precipitated in DCM and hexane as it
was much more soluble than the di-coupled compounds, so it was left as an oil, but TLC analysis
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only showed one product. All compounds were dried in vacuo for at least 48 hours before
testing. Deprotected compounds were used without further purification, including those with the
small contamination. The yields for the protected and deprotected compounds are listed in Table
1.
Table 1: Yields of protected AABA compounds after column chromatography and after
HCl/dioxane Deprotection.
Compound (#)
6
12
19
19s

Protected Yield (%)
73
60
84
62

Post-Deprotection Yield (%)
89
35
72
92

3.2: NMR Spectra
Synthesis of pure protected compounds was confirmed by 1H and 13C NMR
spectroscopy. Only the NMR spectra of some deprotected compounds are pictured due to
problems with peak resolutions. All peaks for each compound are reported in the figure captions
in Figures 19-26.
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3.2.1: Compound 6 Protected

Figure 19: 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 7.2 Hz, 1H), 7.14 (t, J = 7.1 Hz, 1H), 7.03
(dd, J = 9.6, 5.0 Hz, 1H), 6.90 – 6.81 (m, 4H), 6.76 (d, J = 8.0 Hz, 1H), 5.76 (d, J = 7.4 Hz, 1H),
4.16 (d, J = 4.6 Hz, 1H), 3.79 (s, 4H), 3.77 – 3.62 (m, 2H), 2.61 (ddd, J = 49.4, 12.7, 6.5 Hz, 1H),
2.12 – 1.75 (m, 1H), 1.42 (s, 5H), 1.35 (s, 5H).
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3.2.2: Compound 12 Protected

Figure 20: 1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 7.1 Hz, 2H), 7.25 (dd, J = 14.5, 6.7 Hz,
2H), 7.19 – 7.12 (m, 2H), 7.01 – 6.80 (m, 10H), 5.81 (d, J = 7.2 Hz, 1H), 5.04 (s, 4H), 4.11 (d, J
= 4.9 Hz, 1H), 3.86 – 3.63 (m, 10H), 2.71 – 2.45 (m, 2H), 2.10 – 1.75 (m, 2H), 1.38 (d, J = 40.6
Hz, 18H).

29

Figure 21: 13C NMR (101 MHz, CDCl3) δ 171.75 (s), 159.83 (s), 156.83 (s), 155.53 (s), 139.05
(s), 130.27 (s), 129.61 (s), 127.91 (s), 127.74 (s), 120.88 (s), 119.42 (s), 113.30 (s), 112.69 (s),
111.81 (s), 81.23 (s), 79.12 (s), 69.91 (s), 55.20 (s), 53.55 (s), 52.36 (s), 50.84 (s), 29.32 (s),
28.47 (s), 27.93 (s).
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3.2.3: Compound 12 Deprotected

Figure 22: 1H NMR (400 MHz, CDCl3) δ 8.45 (s, 3H), 7.56 (d, J = 30.0 Hz, 2H), 7.19 (s, 4H),
6.80 (d, J = 29.6 Hz, 10H), 5.01 (d, J = 12.3 Hz, 4H), 4.49 (s, 4H), 4.10 (s, 1H), 3.66 (s, 8H),
2.63 (s, 2H).
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3.2.4: Compound 19 Protected

Figure 23: 1H NMR (400 MHz, CDCl3) δ 7.47 (dd, J = 16.3, 7.3 Hz, 4H), 7.33 – 7.26 (m, 2H),
7.21 – 7.03 (m, 6H), 6.92 (dd, J = 12.1, 7.8 Hz, 4H), 5.72 (d, J = 7.4 Hz, 1H), 5.14 (s, 4H), 4.09
(d, J = 5.1 Hz, 1H), 3.70 (q, J = 14.5 Hz, 4H), 2.67 – 2.44 (m, 2H), 2.06 – 1.74 (m, 2H), 1.44 –
1.30 (m, 18H).
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Figure 24: 13C NMR (101 MHz, CDCl3) δ 171.74 (s), 161.57 (s), 159.12 (s), 156.58 (s), 155.46
(s), 130.29 (s), 129.43 (d, J = 8.2 Hz), 127.98 (s), 127.75 (s), 124.60 (s), 124.46 (s), 124.24 (d, J
= 3.5 Hz), 121.03 (s), 115.34 (s), 115.13 (s), 111.72 (s), 81.24 (s), 79.13 (s), 63.81 (d, J = 4.4
Hz), 53.48 (s), 52.21 (s), 50.73 (s), 29.31 (s), 28.40 (s), 27.88 (s).
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3.2.5: Compound 19s: Protected

Figure 25: 1H NMR (400 MHz, CDCl3) δ 7.48 (t, J = 7.2 Hz, 1H), 7.35 – 7.04 (m, 5H), 6.93 (t, J
= 8.0 Hz, 2H), 5.76 (d, J = 6.8 Hz, 1H), 5.15 (s, 2H), 4.21 (d, J = 4.7 Hz, 1H), 3.82 (s, 2H), 2.67
(dd, J = 16.3, 10.9 Hz, 2H), 2.03 – 1.71 (m, 3H), 1.42 (d, J = 2.1 Hz, 18H).
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Figure 26: 13C NMR (101 MHz, CDCl3) δ 171.91 (s), 161.73 (s), 159.27 (s), 156.49 (s), 155.60
(s), 129.99 (s), 129.71 (d, J = 8.1 Hz), 129.50 (d, J = 4.0 Hz), 128.64 (s), 128.24 (s), 124.37 –
124.15 (m), 120.99 (s), 115.39 (d, J = 21.1 Hz), 111.66 (s), 81.51 (s), 79.33 (s), 63.93 (d, J = 4.3
Hz), 53.15 (s), 48.89 (s), 45.27 (s), 32.31 (s), 28.36 (s), 27.98 (s).
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3.3: Patch Clamp Data: Dose Response Curves and Current Traces
Functional properties of the synthesized compounds were tested using whole-cell
recording of voltage clamped HEK293 cells, which were transfected with the corresponding
transporter DNA’s. For non-competitive experiments of cells transfected with ASCT2, inwardly
directed currents represent the 1 mM alanine control. The inward current is a result of increased
leak anion conductance of SCN- through ASCT2’s anion conducting pore down its concentration
gradient from the cytosol to the extracellular solution. Apparent outward currents for these
experiments are the result of the application of a compound that inhibits the leak anion
conductance. To generate a dose response curve for these experiments, the current relative to the
current produced by the highest inhibitor concentration is plotted over increasing concentrations
of inhibitor and fitted to a Michaelis-Menten like equation to obtain the Ki values found in Table
2. For competitive experiments conducted with either hASCT2 or rSNAT2, the decrease in the
magnitude of the inwardly directed alanine current is measured with the application of increasing
inhibitor concentrations and fit to a Michaelis-Menten like curve after plotting the value of these
currents relative to the alanine control up to the highest inhibitor concentration used. The Ki
values obtained for these “competition experiments” represent the Ki value of the compound at a
concentration of 200 μM alanine.
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3.3.1: Compound 6

Figure 27: Compound 6 dose response curves and current recording traces for hASCT2 (A,B),
rASCT2 (C,D), and rSNAT2 (E,F). SNAT2 experiments were done with increasing inhibitor
concentrations in the presence of constant 200 μM Ala.

Compound 6 was one of the two compounds to show significant apparent outwardly
directed currents in a dose dependent manner for hASCT2 and rASCT2, indicative of inhibitory
behavior. However, while application of increasing concentrations of the compound to HEK293
cells expressing rASCT2 resulted in a dose response relationship that started saturating at high
concentrations, currents elicited in hASCT2 increased with concentration in a linear fashion and
not a hyperbolic curve. Therefore, no Ki could be determined for hASCT2 (Figs. 27A & B).
From the dose response curve for rASCT2 (Figs. 27C & D) a Ki of 74.2 ± 23.4 μM was
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determined. It should be noted that these values were obtained in the absence of transported
substrate, alanine, and, thus, reflect intrinsic Ki values for ASCT2s.
For SNAT2, in contrast, no outward currents were observed in the absence of alanine,
either in the presence or absence of SCN-, indicating that compound 6 was unable to block leak
anion current in this transporter. For this reason, compound 6 was applied in the presence of
alanine, to test whether it was able to inhibit the alanine-induced transport current. As shown in
Fig. 27F, compound 6 reduced inwardly directed alanine transport current in a dose dependent
manner. While it was not possible to fully block transport current, given the limited accessible
concentration range due to solubility problems at concentrations higher than 200 μM, a dose
response curve of the blocking effect could be constructed (Fig. 27E). Analysis of the dose
response relationship with equations found in Figure 6 resulted in a Ki of 50.4 ± 8.4 μM for
rSNAT2. Clearly, these data show that compound 6 is a more potent inhibitor for SNAT2 than
for ASCTs.
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3.3.2: Compound 12

Figure 28: Compound 12 dose response curves and current recording traces for hASCT2
(A,C,D), rASCT2 (B,E,F), and rSNAT2 (G,H). All dose response curves were done under
competitive inhibition experiments with 200 μM Ala.

Small apparent outwardly directed currents were produced in hASCT2 HEK293 cells by
application of high concentrations (400 μM) of compound 12, but virtually no response was seen
below concentrations of 400 μM in either hASCT2 or rASCT2 (Figs. 28A & B). For both
hASCT2 and rASCT2 expressing HEK293 cells, competitive experiments with 200 μM alanine
showed some inhibition at concentrations greater than 100 μM, however, the data for both could
not be fit to obtain a Ki value for either transporter (Figs. 28C-28F). In SNAT2 expressing cells,
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no outward or inward currents were produced in the absence of alanine, but in the presence of
alanine, showed inhibition in a dose dependent manner and the data fit to a Ki value of 20.8 ±
12.3 μM (Fig. 28G). However, compound 12, like compound 6, could not completely block the
alanine induced transport current (Fig. 28H). This is seen for every compound that is a SNAT2
inhibitor.
3.3.3: Compound 19

Figure 29: Compound 19 dose response curves and current recording traces for hASCT2 (A,B),
rASCT2 (C,D), and rSNAT2 (E,F). SNAT2 experiments were done with increasing inhibitor
concentrations in the presence of constant 200 μM Ala.
Compound 19 showed significant outward currents for both hASCT2 and rASCT2, which
were concentration dependent with Ki values of 41.1 ± 12.3 μM and 34.9 ± 13.4 μM (Figs. 29A29D). The Ki values obtained here indicate that compound 19 has the highest binding affinity to
ASCT2 out of all the tested compounds. As for compound 6, compound 19 did not elicit currents
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in rSNAT2-transfected cells in the absence of alanine. However, inhibition of alanine-induced
transport currents was observed, but did not saturate at concentrations up to 200 μM (Fig. 29E)
Inhibition of rSNAT2 by compound 19 had the lowest binding affinity for rSNAT2 out of all the
tested compounds with a Ki value of 168.9 ± 32.1 μM (Fig. 29E & F).
3.3.4: Compound 19s

Figure 30: Compound 19s current traces for hASCT2 (A), rASCT2 (B), and rSNAT2 (C). Dose
response curves were not plotted for this compound as there was little to no response for each
protein with increasing applications of inhibitor.
The analogue of compound 19, 19s, with a single-coupled side chain showed little
outward current at the highest concentration tested using hASCT2, 200 μM. Currents below 200
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μM inhibitor showed no response (Fig. 30A). rASCT2 cells showed no response even at 200 μM
inhibitor (Fig. 30B). These results indicate that compound 19s is not an inhibitor of ASCT2.
Competitive inhibition experiments were not done for these two transporters. For rSNAT2,
compound 19s was tested in the presence of alanine. At concentrations up to 600 μM, there was
virtually no inhibition of the alanine-induced inward transport current (Fig. 30C). Together, these
data suggest that compound 19s is ineffective as an inhibitor with respect to both ASCT2 and
SNAT2.
3.3.5: V-9302

Figure 31: V-9302 dose response curves and current recording traces for hASCT2 (A,C),
rASCT2 (B,D) and rSNAT2 (E,F). The key used for B is the same for A and the key for D is the
same for C.
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V-9302 is the only inhibitor from the aminobutyric acid derivatives published by Schulte
et al. (2016 & 2018), that is commercially available. Therefore, this compound was not
synthesized, but purchased from MedChem Express. V-9302 was reported to inhibit ASCT2
with low micromolar affinity (Schulte, M. et al., 2018). In contrast to these literature results,
inhibitory function could not be detected in the work presented here. Very small apparently
outward currents were visible for hASCT2 at 200 μM inhibitor but not for rASCT2 (Figs. 31A &
B). At lower concentrations, current responses were too small to be analyzed (< 5 pA). To test
for block of alanine-induced current, V-9302 was co-applied with 200 μM alanine (Figs. 31C &
D). No inhibition of the alanine current was observed in the accessible concentration range.
Therefore, dose response curves for competitive alanine experiments for hASCT2 and rASCT2
are not shown.
For rSNAT2, V-9302 inhibited alanine-induced inward transport current, although no
complete block was observed at the highest concentration tested (Fig. 31F). After plotting the
current vs. the V-9302 concentration, an apparent Ki value of 17.7 ± 5.5 μM was obtained (Fig.
31E). However, due to the block of alanine current of only 40% at maximum V-9302
concentration, it is not clear how reliable this Ki value is. Clearly, a competitive inhibition
mechanism would require the compound to completely block alanine-induced transport current.
This is not the case in the data presented here. Therefore, either the data are not of sufficient
quality to determine Ki for competitive blocking, or the mechanism of inhibition is different from
a competitive mechanism. Additional experiments will have to be performed to differentiate
between these possibilities. Overall, each tested compound shows an inhibitory effect towards
rSNAT2 by inhibiting the inward alanine substrate induced current. In addition, the data shows
evidence that slight changes in structure in the side chains of the tested AABA compounds

43

significantly change the inhibitory character of these compounds toward the ASCTs and SNAT2.
In addition, while the data for each SNAT2 experiment fit to a dose response curve to a Ki value,
the tested compounds did not completely inhibit the alanine induced currents. Future
experimentation with higher concentrations is difficult due to the poor solubility of most of these
compounds at concentrations greater than 200 μM. Experiments in the future with lower alanine
concentrations are a possibility to examine if the alanine induced current is inhibited completely
by these compounds. The summary of the Ki values obtained for each compound for each
respective transporter is illustrated in Table 2,
Table 2: Ki values obtained for each compound. All values marked with N/A indicate that a Ki
value could not be calculated due to poor binding affinity of the compound to the respective
transporter. All Ki values obtained for rSNAT2 were obtained in the presence of constant 200
μM Ala.
Compound
6
12
19
19s
V-9302

Ki (μM): hASCT2
> 400
N/A
41.1 ± 12.3
N/A
N/A

Ki (μM): rASCT2
74.2 ± 23.4
N/A
34.9 ± 13.4
N/A
N/A
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Ki (μM): rSNAT2
50.4 ± 8.4
20.8 ± 12.3
168.9 ± 32.1
N/A
17.7 ± 5.5

Chapter 4: Discussion
The synthesis of small molecule inhibitors of ASCT2 is a widely growing area of
research due to the upregulation of this protein in different cancers such as breast and prostate
cancer (Wang, Q., et al., 2015; Van Geldermalsen, M., et al., 2016). Experiments using shRNA
knockdown of ASCT2 in vivo and in vitro have shown significant decreases in tumor growth and
metastasis, in addition to decreased tumor growth using chemical inhibition of ASCT2 (Wang,
Q. et al., 2015). However, the lack of specific, potent ASCT2 inhibitors prevents the use of
chemical inhibition of ASCT2 in clinical settings and the development of these inhibitors would
be an invaluable tool in treating different cancers by glutamine starvation. While AABA
inhibitors have been shown to slow tumor growth both in vivo and in vitro, the specificity of
these compounds in the inhibition of glutamine uptake by ASCT2 has been contested in other
studies (Schulte, M., et al. 2016 & 2018; Bröer, A., et al. 2018). Instead, it is suspected that these
AABA inhibitors are not specific to ASCT2 at all, but rather SNAT2 and LAT1. However, these
studies only picked two of the more potent inhibitors tested by Schulte et al. and did not
characterize other compounds in the library of purported ASCT2 inhibitors (Bröer, A. et al.,
2018). Additionally, no prior studies have characterized the binding affinity of these inhibitors
using electrophysiological methods and reported accurate Ki values.
My electrophysiological characterization of these inhibitors on ASCT2 and SNAT2
shows evidence that these compounds are SNAT2 blockers. Some compounds, such as
compound 6 and 19, have additional inhibitory effects on ASCT2 (Fig. 27 & 29), and the others,
12, 19s, and V-9302, show little to none (Fig. 28, 30, &31). The two AABA compounds tested
by Bröer, A., et al., Compound 12 and V-9302, show the weakest response to both hASCT2 and
rASCT2. In normal electrophysiological experiments, a small, apparent outward current is only
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seen with 400 μM inhibitor for hASCT2, while there is no response from rASCT2 at the same
concentration of inhibitor with compound 12 (Figure 28A & 28B). Competitive experiments
with 200 μM alanine show a small amount of inhibition as compared to the control for both
rASCT2 and hASCT2 (Figure 28 C-F), but not at the binding affinities reported in the literature.
V-9302 shows a similar trend, with some current response at 200 μM for hASCT2, but no
response for rASCT2 (Figure 31A & 31B). The data presented here contrast the results reported
by Schulte et al. (2016 & 2018), who reported that compound 12 and V-9302 had high affinity
interaction specifically to ASCT2. My electrophysiological characterization points to evidence
that the clinical effects of these compounds are unlikely caused by block of ASCT2 because of
the poor interaction with ASCT2. Instead, the clinical effects of decreased glutamine uptake are
likely due to the inhibition of different amino acid transporters, such as SNAT2.
In addition, out of all the compounds tested, 12 and V-9302 potentially show the highest
binding affinity to rSNAT2, with Ki values of 20.8 ± 12.3 μM and 17.7 ± 5.5 μM respectively
(Table 2). V-9302, however, only shows a decrease of approximately 40% in a dose dependent
manner and solubility issues prevent electrophysiological testing at concentrations greater than
200 μM. Therefore, it is not known how reliable the Ki value of V-9302 for SNAT2 is and there
is a possibility that it could be higher or that inhibition occurs by a different mechanism than
competitive inhibition. In addition, future experiments may be performed using lower
concentrations of alanine to see if there is complete inhibition of the alanine induced current at
lower concentrations. Importantly, these are the first non-transportable substrate blockers
identified for SNAT2, which are not substrate-like inhibitors, such as α-(methylamino) isobutyric
acid (MeAIB) (Yao, D. et al., 2000). This data shows increasingly supporting evidence that two
of the most potent purported ASCT2 inhibitors actually have very poor binding affinity to
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ASCT2 and instead rather act on SNAT2. However, two of the other compounds, 6 and 19, were
weaker inhibitors of SNAT2 but showed inhibitory effects toward hASCT2 and rASCT2.
Compound 19 demonstrated the best binding affinity to both hASCT2 and rASCT2 out of all the
compounds tested with Ki values of 41.1 ± 12.3 μM for hASCT2 and 34.9 ± 13.4 μM for
rASCT2 (Table 2). Interestingly, this compound had the lowest binding affinity to SNAT2
(Table 2). Overall, compound 6 showed a similar trend, but had slightly poorer binding affinity
to rASCT2 than compound 19. In addition, compound 6 showed an interesting current response
to hASCT2, in which saturation could not be reached, even at concentrations of 400 μM inhibitor
(Figure 27A). These data show evidence that slight modifications in the side chains of the AABA
compounds can significantly change the inhibitory characteristics of the compounds.
Previously reported inhibitors of ASCT2 such as GPNA and other studies of the binding
site of the SLC1A family have provided a scaffold for the synthesis of ASCT2 inhibitors
(Esslinger, C. S. et al., 2005; Corti, A. et al., 2019). Later work in this area has shown that
increasing the hydrophobicity of the side chains on inhibitory compounds led to increased
inhibitor binding affinity (Albers, T. et al, 2012; Singh, K. et al., 2017). For example, studies
conducted by Singh et al. (2017) found that increasing the hydrophobicity of the side chains of
single substituted benzylproline derivatives was correlated with an increase in apparent binding
affinity. In fact, electrophysiological characterization revealed a potent biphenyl benzylproline
inhibitor with a Ki value of 3 ± 2 μM (Singh, K. et al., 2017). A similar trend was noted for
inhibitory serine derivatives in a study conducted by Albers et al. (2012), which concluded that
inhibitors of ASCT2 preferentially bind to the outward open conformation of ASCT2, in contrast
to substrates, which preferentially preferred the closed-loop, outward occluded conformation.
Results from this study found that the increased binding affinity was associated with long
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hydrophobic side chains with aromatic bulk. However, side chains that had too much aromatic
bulk, such as naphthyl, did not inhibit strongly, suggesting that too much aromatic bulk may lead
to poor inhibition (Albers, T. et al., 2012). ASCT2 homology models have shown that there are
two hydrophobic pockets in ASCT2, pocket A and B (Colas, C. et al., 2015). The results from
the study conducted by Singh, et al. (2017) indicated that these inhibitors likely occupy pocket B,
with only a single hydrophobic side chain (Singh, K. et al., 2017). Schulte et al. (2016)
performed similar docking experiments with AABA inhibitors and found similar interactions
with a hydrophobic pocket of ASCT2, in addition to interactions with a hairpin loop that likely
closes over the substrate binding site. This interaction could prevent closing of this loop and be a
possible mechanism of inhibition (Schulte, M. et al., 2016). However, based on the results from
my electrophysiological characterization, it is possible that the side chains for compound 12 and
V-9302 are too bulky and have poor binding interaction with one of the hydrophobic binding
pockets. Compound 6 may have better binding affinity due to the shorter chain length. In
addition, the results from compound 19 indicate that the position of a substituent (fluoro) may
significantly alter the binding affinity to ASCT2 at the given chain length, as V-9302 and
compound 19 have an almost identical side chain length. Additionally, fluorine groups have been
shown to increase the binding affinity of certain drugs by various interactions, including one
with a peptide bond (Müller, K. et al., 2007). This may also explain the increased affinity for
ASCT2 of compound 19. These results indicate that while bulky, hydrophobic, aromatic groups
are characteristic of better binding affinity for ASCT2 inhibitors, it is likely that the side chain
length is an important factor in determining this binding affinity and side chains that are too long
will have weak to no apparent inhibitory binding affinity to ASCT2.

48

SNAT2 transports short chain aliphatic amino acids, with a preference for alanine. It is
also a glutamine transporter (Yao, D. et al., 2000). SNAT2 is an isoform of system A activity, an
important Na+ dependent intracellular amino transport activity that occurs in many tissues
throughout the human body. System A activity, unlike other amino acid transport systems such
as the ASC’s, also recognizes N-methylamino acids such as α-(methylamino)isobutyric acid
(MeAIB). MeAIB, is a substrate like competitive inhibitor for SNAT2 and the other proteins
associated with system A activity such as SNAT1 and SNAT4 (Yao, D. et al., 2000; Nishimura,
T. et al., 2014). My electrophysiological characterization provides conclusive evidence that the
tested AABA compounds are the first known, non-substrate like inhibitors of SNAT2. These
results can be useful in further understanding the structure, mechanism, and binding interactions
of SNAT2, as current structural data for SNAT2 is scarce. There is no crystal structure present
for SNAT2 in the literature. However, some important structural and functional components of
SNAT2 have been identified, including a difsulfide bridge, a conserved Na+ binding site, and a
leak anion conductance (Chen, C. et al., 2000; Zhang, Z., & Grewer, C., 2007; Zhang, Z. et al.,
2009). In addition to this, SNAT2 and its membrane transport family (SLC38), have been
reported to be a member of a superfamily of transporters for cations and organic substrates,
notably the SLC5 and 6 family of proteins. Specifically, it was reported that the SLC5/6 family
of proteins contain a similar structural fold to the SLC38 family (Zhang, Z. et al., 2009).
Compound 19s showed a small current response in hASCT2 at 200 μM inhibitor
concentration, no inhibition of rASCT2, and no inhibition of rSNAT2 even at 600 μM inhibitor
(Figure 30). Lack of inhibitory response in ASCT2 was expected due to the drastic change in
structure of the inhibitor by removal of a single side chain. Based on our electrophysiological
data, the low micromolar IC50 (high apparent affinities) values reported by Schulte et al. (2016 &

49

2018) for the library of AABA compounds may have been obtained from the combined
inhibition of glutamine uptake by the inhibition of both SNAT2 and ASCT2, while some
compounds may have only inhibited SNAT2. In addition, there is evidence that compound 12
and V-9302 also display inhibitory effects towards another protein, LAT1 (Bröer, A. et al.,
2018). However, electrophysiological current recordings are not useful in the determination of
Ki values for inhibitors specific to LAT1 because of its electroneutral characteristics, so it would
be difficult to confirm this by our electrophysiological methods (Scalise, M. et al., 2018).
Chapter 5: Conclusion
In conclusion, electrophysiological data presented here shows evidence that AABA
compounds are more likely to be to SNAT2 inhibitors, rather than ASCT2 inhibitors. These
compounds, specifically compound 12 and V-9302, can be used to further understand the
binding site of SNAT2 and help in the development of pharmacophore models that allow the
quantification of structure-junction parameters of amino acid derivative interaction with the
binding site. However, the relatively high binding affinity of compound 19 opens a door for
further exploration into these AABA inhibitors specifically for ASCT2. As indicated by the
results, slight modifications to the side chains show significant changes to the binding affinity of
these inhibitors towards ASCT2. There was a total of 23 characterized AABA inhibitors in the
study done by Schulte et al. (2016) and further electrophysiological characterization of these
compounds is necessary to find those with potentially higher binding affinities for ASCT2.
While these compounds can no longer be reported as specific ASCT2 inhibitors, they are
potentially useful in further understanding of the binding site for both ASCT2 and SNAT2.
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